ArticleEndocrinology2012
Angiotensin receptor blockade increases pancreatic insulin secretion and decreases glucose intolerance during glucose supplementation in a model of metabolic syndrome.
Article in Endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 55 citations in OpenAlex.
- Partial body mass regain attenuates lipid utilization and alters the hepatic lipidome linked to HDL dysfunction during metabolic syndrome in male rats.Physiological reports · 2026Article
- Pseudocannabinoid H4CBD improves glucose response during advanced metabolic syndrome in OLETF rats independent of increase in insulin signaling proteins.American journal of physiology. Regulatory, integrative and comparative physiology · 2024Article
- Angiotensin receptor blockade with olmesartan alleviates brain pathology in obese OLETF rats.Clinical and experimental pharmacology & physiology · 2023Article
- Chronic ATAmerican journal of physiology. Endocrinology and metabolism · 2021Article
- Oxylipin responses to fasting and insulin infusion in a large mammalian model of fasting-induced insulin resistance, the northern elephant seal.American journal of physiology. Regulatory, integrative and comparative physiology · 2021Article
- Article
- Two important controversial risk factors in SARS-CoV-2 infection: Obesity and smoking.Environmental toxicology and pharmacology · 2020Review
- Partial Body Mass Recovery After Caloric Restriction Abolishes Improved Glucose Tolerance in Obese, Insulin Resistant Rats.Frontiers in endocrinology · 2020Article
- AMPK: a balancer of the renin-angiotensin system.Bioscience reports · 2019Review
- Relationship between diet/exercise and pharmacotherapy to enhance the GLP-1 levels in type 2 diabetes.Endocrinology, diabetes & metabolism · 2019Review
- Pancreatic AT1aR Deficiency Decreases Insulin Secretion in Obese C57BL/6 Mice.American journal of hypertension · 2019Article
- Angiotensin receptor and tumor necrosis factor-α activation contributes to glucose intolerance independent of systolic blood pressure in obese rats.American journal of physiology. Renal physiology · 2018Article
- Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats.Hypertension research : official journal of the Japanese Society of Hypertension · 2018Article
- Chronic AT1 blockade improves glucose homeostasis in obese OLETF rats.The Journal of endocrinology · 2018Article
- Diagnostic imaging in the management of patients with metabolic syndrome.Translational research : the journal of laboratory and clinical medicine · 2018Review
- Angiotensin receptor blockade improves cardiac mitochondrial activity in response to an acute glucose load in obese insulin resistant rats.Redox biology · 2018Article
- Exogenous thyroxine improves glucose intolerance in insulin-resistant rats.The Journal of endocrinology · 2017Article
- A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats.Hypertension research : official journal of the Japanese Society of Hypertension · 2016Article
- ACE2 deficiency reduces β-cell mass and impairs β-cell proliferation in obese C57BL/6 mice.American journal of physiology. Endocrinology and metabolism · 2015Article
- Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease.World journal of diabetes · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Renin-angiotensin system blockade improves glucose intolerance and insulin resistance, which contribute to the development of metabolic syndrome. However, the contribution of impaired insulin secretion to the pathogenesis of metabolic syndrome is not well defined. To assess the contributions of angiotensin receptor type 1 (AT₁) activation and high glucose intake on pancreatic function and their effects on insulin signaling in skeletal muscle and adipose tissue, an oral glucose tolerance test (oGTT) was performed in five groups (n = 10/group) of rats: 1) lean strain-control 2) obese Otsuka Long-Evans Tokushima Fatty (OLETF), 3) OLETF + angiotensin receptor blocker (ARB; 10 mg/kg · d olmesartan for 6 wk; OLETF ARB), 4) OLETF + 5% glucose water (HG) for 6 wk (OLETF HG), and 5) OLETF + HG + ARB (OLETF HG/ARB). The glucose response to the oGTT increased 58% in OLETF compared with lean-strain control, whereas glucose supplementation increased it an additional 26%. Blockade of angiotensin receptor reduced the oGTT response 19% in the ARB-treated groups and increased pancreatic insulin secretion 64 and 113% in OLETF ARB and OLETF HG/ARB, respectively. ARB treatment in OLETF ARB and OLETF HG/ARB did not have an effect on insulin signaling proteins in skeletal muscle; however, it reduced pancreatic AT₁ protein expression 20 and 27%, increased pancreatic glucagon-like peptide-1 (GLP-1) receptor protein expression 41 and 88%, respectively, and increased fasting plasma GLP-1 approximately 2.5-fold in OLETF ARB. The results suggest that improvement of glucose intolerance is independent of an improvement in muscle insulin signaling, but rather by improved glucose-stimulated insulin secretion associated with decreased pancreatic AT₁ activation and increased GLP-1 signaling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.